Tumor Profiling Improves Breast Cancer PFS

    Cancer Discovery
    |December 10, 2021
    PubMed

    Insights

    Genomically guided targeted therapy improves outcomes for metastatic breast cancer patients. This approach enhances progression-free survival by targeting specific tumor mutations effectively.

    Area of Science:

    • Oncology
    • Genomics
    • Pharmacology

    Background:

    • Metastatic breast cancer (MBC) presents significant treatment challenges.
    • Identifying actionable mutations is crucial for effective therapy selection.

    Discussion:

    • Genomic profiling of tumors allows for personalized treatment strategies.
    • Targeted therapies exploit specific molecular alterations in cancer cells.

    Key Insights:

    • Genomically guided targeted therapy significantly improves progression-free survival in MBC.
    • Tumors with specific, targetable mutations respond well to this precision medicine approach.

    Outlook:

    • Further research into novel targeted therapies and resistance mechanisms is warranted.
    • Wider adoption of genomic testing can optimize treatment paradigms for MBC patients.

    Related Concept Videos

    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    6.6K
    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
    478
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.9K